Francisco Javier
López Jiménez
Profesor/a Asociado/a en CC. de la Salud
Hospital del Mar
Barcelona, EspañaPublicacions en col·laboració amb investigadors/es de Hospital del Mar (5)
2024
2019
-
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group)
Annals of Oncology, Vol. 30, Núm. 4, pp. 612-620
2017
2014
-
Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: A multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study
British Journal of Haematology, Vol. 164, Núm. 5, pp. 668-674